Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
The shifting landscape of KATP channelopathies and the need for 'sharper' therapeutics.
Future Med Chem. 2016 May;8(7):789-802. doi: 10.4155/fmc-2016-0005. Epub 2016 May 10.
Future Med Chem. 2016.
PMID: 27161588
Free PMC article.
Review.
Small-molecule inhibitors (e.g., sulfonylurea drugs) or activators (e.g., diazoxide) acting on SUR1 or SUR2 have been used clinically for decades to manage the inappropriate secretion of insulin in patients with Type 2 diabetes, hyperinsulinism and intractable hypertension …
Small-molecule inhibitors (e.g., sulfonylurea drugs) or activators (e.g., diazoxide) acting on SUR1 or SUR2 have been used clinically for de …
[A new type of ATP-sensitive potassium channelopathy : Cantu syndrome].
Hiraki Y, Takanari H.
Hiraki Y, et al.
No To Hattatsu. 2016 Sep;48(5):325-31.
No To Hattatsu. 2016.
PMID: 30010274
Review.
Japanese.
These diseases are referred to as KATP channelopathies. Recently, Cantu syndrome (CS), which was found to be caused by mutations in the ABCC9 or KCNJ8 gene, was newly added to the list of KATP channelopathies. ...
These diseases are referred to as KATP channelopathies. Recently, Cantu syndrome (CS), which was found to be caused by mutatio …
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.